Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
BURLINGTON, Mass., April 25, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business operations and report its first-quarter 2017 financial results on Thursday, May 4, 2017, at 4:30 p.m. ET.
The dial-in number for the conference call is (855) 770-0022 for domestic participants and (908) 982-4677 for international participants, with Conference ID #11984746. A live webcast of the conference call can also be accessed through the “Investors” tab on the Flexion Therapeutics website. A webcast replay will be available online after the call.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA) of the knee. The company's lead product candidate, ZilrettaTM (also known as FX006) is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contact: Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected]
